Objectives: We tried to outline the management of LUTS suggestive of BPO in real life practice in France. In addition, preliminary results regarding switch rates of different initial treatment approaches in primary care are given in order to assess the effectiveness of therapies. Methods: IMS and GERS market data of drugs for LUTS suggestive of BPO in France are presented. In addition, data from the THALES database for 1997 and 1998 containing the patient medical records of 620 French GPs were analysed with special emphasis on the initial management by GPs and switch rate to another treatment option. Results: The prevalence and incidence of LUTS suggestive of BPO is high and more than half of the French LUTS patients receive a medical treatment from their GP. α1-Adrenoceptor antagonists are prescribed most in the management of LUTS suggestive of BPO in France and their use is still increasing. Finasteride is prescribed much less whereas the use of phytotherapy is, although decreasing, still rather high. The switch rate of tamsulosin as initial treatment to another treatment option is low (14.4%), compared to other therapies like terazosin (26.5%), reflecting its favourable benefit/risk ratio in real life practice. Conclusions: In France, the prescription rate of α1-adrenoceptor antagonists, and especially tamsulosin, is high and still growing. Further information is however needed to study the impact of initial treatment choice on the progression of LUTS suggestive of BPO.

1.
Garraway WM, Collins GN, Lee RJ: High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469–471.
2.
Lukacs B: Management of symptomatic BPH in France: Who is treated and how? Eur Urol 1999;36(suppl 3):14–20.
3.
Mann RD, Biswas P, Freemantle S, Pearce G, Wilton L: The pharmacovigilance of tamsulosin: Event data on 12,484 patients. BJU Int 2000;85:446–450.
4.
Wilton, L, Pearce G, Edet E, Freemantle S, Stephens MDB, Mann RD: The safety of finasteride used in benign prostatic hypertrophy: A non-interventional observational cohort study in 14772 patients. Br J Urol 1996;78:379–384.
5.
Michel MC, Mehlburger L, Bressel H-U, Schumacher H, Schäfers RF, Goepel M: Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: Does co-morbidity alter tolerability? J Urol 1998;160:784–791.
6.
Michel MC, Bressel H-U, Mehlburger L, Goepel M: Tamsulosin: Real life clinical experience in 19,365 patients. Eur Urol 1998;34(suppl 2):37–45.
7.
Lukacs B, Blondin P, MacCarthy C, Du Boys B, Grippon P, Lassale C: Safety profile of 3 months’ therapy with alfuzosin in 13,389 patients suffering from benign prostatic hypertrophy. Eur Urol 1996;29:29–35.
8.
Farmer RDT, Williams T, Clifford G, Logie J, Macrae KD: Changes in the patterns of management of benign prostatic hyperplasia in the United Kingdom: 1991–1998. Eur Urol 2000;37(suppl 2):118 (abstract 471).
9.
de Mey C: α1-Blockers for BPH: Are there differences? Eur Urol 1999;36(suppl 3):52–63.
10.
Djavan B, Marberger M: A meta-analysis on the efficacy and tolerability of α1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999;36:1–13.
11.
Chapple CR: Pharmacotherapy for benign prostatic hyperplasia – the potential for α1-adrenoceptor subtype-specific blockade: Br J Urol 1998;81(suppl 1):34–47.
12.
Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533–539.
13.
Debruyne FMJ, Jardin A, Colloi D, Resel L, Witjes WP, Delauche-Cavallier MC, McCarthy C, Geffriaud-Ricouard C: Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. Eur Urol 1998;34:169–175.
14.
Kirby R, Altwein JE, Bartsch G, Boyle P, Jardin A, Roehrborn CG: Results of the PREDICT (Prospective European Doxazosin and Combination Therapy) trial. J Urol 1999;161(suppl):266 (abstract 1027).
15.
Fitzpatrick JM: Phytotherapy for treatment of benign prostatic hyperplasia: Case not proven. Urology 1999;53:462–464.
16.
Denis LJ: Editorial review of ‘Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1098 patients’. Prostate 1996;29:241–242.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.